DBV Technologies S.A. (DBVT) vs Sagimet Biosciences Series A (SGMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sagimet Biosciences Series A (SGMT) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 21.0% versus a loss of 31.4%. Sagimet Biosciences Series A is the larger company by market cap ($625.4 million vs $604.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | SGMT |
|---|---|---|
| Share price | $9.63 | $8.82 |
| Market cap | $604.92M | $625.41M |
| 1-day change | -1.49% | -0.68% |
| YTD return | -49.03% | +50.00% |
| 1-year return | -31.39% | +20.98% |
| 5-year return | -7.83% | — |
| EPS (TTM) | $-3.50 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.19 | $11.45 |
| 52-week low | $9.58 | $4.50 |
| Distance from 52-week high | -63.24% | -22.96% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +301.35% | +216.44% |
| Average volume | 331.54K | 1.23M |
| Shares outstanding | 62.85M | 70.34M |
| Employees | 170 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SGMT has outperformed DBVT by 52.4 percentage points over the past year.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 170 employees
About Sagimet Biosciences Series A
SGMT stock →Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
DBVT vs SGMT FAQ
Which is bigger, DBV Technologies S.A. or Sagimet Biosciences Series A?
Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $625.41M compared with $604.92M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or SGMT?
SGMT returned +20.98% over the past 12 months, compared with -31.39% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Sagimet Biosciences Series A in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for DBV Technologies S.A. and Biotechnology: Pharmaceutical Preparations for Sagimet Biosciences Series A.